Clinical Data Presented at ARVO Showing NovaBay’s Avenova Reduces Bacteria on Ocular Skin Surface by More than 90%

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) a biopharmaceutical company focusing on commercializing its Avenova® Lid and Lash Hygiene product for the domestic eye care market, announces the presentation of clinical data demonstrating that Avenova reduced the bacterial load on the ocular skin surface by more than 90% in 20 minutes without affecting the diversity in the type of bacteria remaining. Results of the Avenova study were discussed in an oral prese